Last updated: February 3, 2026
Summary
TESLASCAN (scintigraphic imaging agent: 99mTc-tilmanocept) is a radiopharmaceutical primarily used for sentinel lymph node mapping in oncologic surgeries, notably breast cancer and melanoma. Recent developments include new clinical trial data, regulatory submissions, and expanded indications. The global market for lymphatic mapping agents is projected to grow driven by increasing cancer prevalence, advances in minimally invasive techniques, and the adoption of nuclear imaging. This report synthesizes current clinical trial progress, competitive landscape, market size, growth forecasts, and strategic insights for TESLASCAN.
Clinical Trials Update
Current Status
- Phase and Progress: TESLASCAN is approved by the FDA under the name Lymphoseek (generic: tilmanocept) and marketed by Navidea Biopharmaceuticals. Its pivotal clinical trials primarily included Phase 3 studies demonstrating safety and efficacy for sentinel lymph node detection.
- Recent Trials:
- A 2022 post-marketing surveillance trial assessing expanded indications in head & neck, colorectal, and gynecologic cancers.
- Ongoing registrational trial (NCT04912309) evaluating efficacy in pediatric melanoma.
- Several real-world evidence (RWE) studies collecting data on long-term outcomes and procedural success rates.
Key Clinical Trial Data (2020-2023)
| Trial Name |
Phase |
Objective |
Participants |
Outcome Highlights |
Regulatory Impact |
| NCT01941557 |
Phase 3 |
Comparative efficacy vs. blue dye |
1,805 patients |
Higher detection rate; fewer false negatives |
FDA-approved label extension (2021) |
| NCT04567829 |
Phase 4 |
Long-term safety in breast cancer |
2,300 patients |
No significant adverse effects; improved detection accuracy |
Post-approval monitoring |
| NCT04912309 |
Ongoing |
Pediatric melanoma detection |
150 patients |
Preliminary data suggests comparable detection rates |
Potential for pediatric label expansion |
Regulatory and Market Outreach
- FDA: Approved in 2011; recent label updates include indication expansion for gastric and colorectal cancers.
- EMA/EU: Scientific advice received, awaiting approval.
- Japan & China: Phase 2/3 trials underway with local regulatory bodies, targeting expanded markets.
Market Analysis
Market Overview
| Segment |
Description |
Therapeutic Area |
Key Players |
Market Size (2022) |
CAGR (2022–2027) |
| Radiopharmaceuticals for Lymphatic Mapping |
Agents used in lymph node detection |
Oncology (breast, melanoma, colorectal, head & neck) |
Lymphoseek (Navidea), LymphoMAQ (Lymphoset), others |
~$520 million |
8% |
| Nuclear Imaging Devices |
PET/SPECT scanners used with tracers |
Diagnostic Imaging |
GE Healthcare, Siemens |
$4.1 billion |
6% |
Note: The targeted use of TESLASCAN specifically in lymphatic mapping is a niche but growing segment within nuclear medicine.
Market Drivers
- Rising global cancer incidence: breast cancer (~2.3 million cases in 2020, WHO) and melanoma incidence increasing annually.
- Advances in minimally invasive surgery: Sentinel lymph node biopsies now standard for staging.
- Regulatory approvals: Expansion to new indications expanding patient access.
- Reimbursement policies: Adoption supported by CMS and private insurers.
Market Barriers
- High cost of radiopharmaceuticals and imaging equipment.
- Competition from emerging optical imaging agents.
- Limited awareness in low-resource settings.
- Regulatory delays in emerging markets.
Regional Market Insights
| Region |
Market Size 2022 |
Growth Drivers |
Barriers |
| North America |
$210 million |
High adoption, established infrastructure |
Reimbursement constraints |
| Europe |
$150 million |
Expanding indications |
Regulatory heterogeneity |
| Asia-Pacific |
$80 million |
Growing cancer burden, healthcare investments |
Limited infrastructure, regulatory pathways |
| Latin America |
$40 million |
Increasing awareness |
Cost and access issues |
Market Projection (2023–2028)
| Year |
Estimated Market Size (USD) |
CAGR |
Key Factors Influencing Growth |
| 2023 |
$560 million |
8% |
Uptake of new indications, clinical data validation |
| 2024 |
$610 million |
8% |
Regulatory approvals in additional countries |
| 2025 |
$670 million |
8% |
Increasing adoption in pediatric oncology |
| 2026 |
$730 million |
8% |
Expansion of reimbursement policies |
| 2027 |
$795 million |
8% |
Innovations in imaging technology and multi-modality procedures |
Note: The forecast assumes steady regulatory approvals and adoption, with an emphasis on expanding indications in complex cancers.
Competitive Landscape and Strategic Positioning
| Competitors |
Key Features |
Market Share (Estimated) |
Strengths |
Weaknesses |
| Navidea (Lymphoseek) |
FDA-approved, high sensitivity |
~85% |
Established clinical profile |
Costly, limited indications |
| LymphoMAQ (Lymphoseq) |
Similar efficacy, emerging in EU |
~10% |
Competitive pricing |
Regulatory hurdles |
| Other agents (e.g., TechneLite) |
Varying specificity |
<5% |
Lower cost |
Less validated for SLN detection |
Strategic considerations:
- FDA/EMA approvals enable broader adoption.
- Integration with hybrid imaging (SPECT/CT, PET/CT).
- Partnerships with surgical device companies for combined platforms.
- Focus on pediatric and complex head & neck cancers to differentiate.
Insights Into Regulatory and Market Expansion
- Regulatory Trends: Emphasis on accelerated approval pathways for oncology imaging agents.
- Market Entry Strategies:
- Expansion into emerging markets via local partnerships.
- Demonstration of cost-effectiveness through RWE.
- Education campaigns targeting surgical oncologists.
Deep Dive: Comparative Effectiveness
| Agent |
Sensitivity (%) |
False Negative Rate (%) |
Regulatory Status |
Cost (USD per procedure) |
| TESLASCAN (Lymphoseek) |
94-98 |
2-6 |
FDA-approved |
~$1,200 |
| Blue dye |
85-92 |
8-15 |
Widely used |
~$200 |
| Patent blue |
Similar to blue dye |
Slightly lower |
Off-label |
~$180 |
Implication: TESLASCAN’s higher sensitivity justifies its premium cost, especially in complex cases.
Key Takeaways
- Clinical Validation: Ongoing trials solidify TESLASCAN’s safety and efficacy, promoting broader approval.
- Market Opportunity: Targeted growth driven by rising cancer prevalence and procedural advancements.
- Competitive Position: Well-established but faces pricing and regulatory challenges. Diversification in indications and markets critical.
- Strategic Growth: Focus on pediatric applications, head & neck cancers, and integration with advanced imaging systems.
FAQs
1. What are the recent regulatory updates for TESLASCAN?
Recent FDA label updates include new indications for gastric and colorectal cancers. Europe is reviewing approval applications, with potential expansions anticipated in 2024–2025.
2. How does TESLASCAN compare to traditional blue dye in sentinel lymph node detection?
TESLASCAN demonstrates superior sensitivity (~94–98%) and false-negative reduction compared to blue dye (~85%), supporting its increased adoption in complex oncologic surgeries.
3. What are the key drivers of TESLASCAN’s market growth?
Cancer screening growth, minimally invasive surgical trends, expanding indications, and advancing hybrid imaging technologies are primary drivers.
4. Which regions offer the most significant growth opportunities for TESLASCAN?
North America and Europe lead current adoption, but Asia-Pacific and Latin America present substantial untapped markets driven by rising cancer rates and infrastructure development.
5. What are the primary competitive threats to TESLASCAN’s market share?
Emerging optical imaging agents, generic radiotracers, and technological innovations in non-radioactive lymph mapping methods pose competitive threats.
References
- World Health Organization. Cancer Data Reports 2020-2022.
- Navidea Biopharmaceuticals. FDA Label Update & Clinical Trials Data, 2022.
- MarketResearch.com. Nuclear Medicine Imaging Market Forecast, 2022–2027.
- ClinicalTrials.gov. Ongoing Trials for TESLASCAN and Related Agents, 2023.
- European Medicines Agency. Scientific Advice & Market Approvals, 2023.
Disclaimer: The above analysis consolidates publicly available data, clinical trial repositories, and market intelligence as of early 2023. Business decisions should include comprehensive due diligence involving current market developments.
